Bladder Cancer Testing FAQs
 NMP-22 Bladder Cancer Marker - Physician Overview

Test at a Glance

Assay:  NMP-22

Diagnosis and Monitoring for:  Bladder Cancer

Clinical Application
Together with other clinically accepted tests and procedures, NMP-22 offers earlier detection in facilitating the diagnosis and management of bladder cancer.

Specific Sample Requirements
A single void urine specimen will be collected at a LifeLabs Patient Service Centre. Specimens must be stabilized immediately upon collection. No appointment is necessary.

Turnaround Time:  3 weeks from time of collection

Advantages of Assay
Noninvasive. Increased sensitivity for low-grade tumors. Testing can be done as early as 5 days post-TURP surgery or cystoscopy.

* Available in Ontario only 1-877-849-3637